TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | 0.00% | 79.54 | 1.2% | $617.34m | |
| AMGN | Amgen Inc. | 0.00% | 177.96 | 1.2% | $579.57m | |
| GILD | Gilead Sciences, Inc. | 0.00% | 67.53 | 0.9% | $547.73m | |
| BIIB | Biogen Inc. | 0.00% | 284.41 | 1.2% | $489.40m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.00% | 294.61 | 2.6% | $305.85m | |
| ILMN | Illumina, Inc. | 0.00% | 270.83 | 3.5% | $228.12m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.00% | 156.97 | 1.9% | $223.27m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.00% | 117.14 | 2.0% | $216.01m | |
| A | Agilent Technologies, Inc. | 0.00% | 64.13 | 1.5% | $205.67m | |
| NKTR | Nektar Therapeutics | 0.00% | 80.58 | 6.0% | $188.74m | |
| INCY | Incyte Corporation | 0.00% | 66.67 | 2.5% | $152.87m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.00% | 89.99 | 16.6% | $124.68m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.00% | 88.28 | 4.4% | $120.50m | |
| EXAS | Exact Sciences Corporation | 0.00% | 52.85 | 25.5% | $108.34m | |
| BLUE | Bluebird Bio, Inc. | 0.00% | 187.00 | 15.7% | $96.24m |
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.